Verubecestat, an oral drug that blocks the production of amyloid-β, did not improve clinical ratings of dementia in patients with prodromal Alzheimer disease, according to a trial in the New England Journal of Medicine.
A total of 1454 participants with mild cognitive impairment and elevated brain amyloid levels were randomized to receive either 12 mg of verubecestat per day, 40 mg of verubecestat per day, or placebo. Cognitive decline was assessed using the Clinical Dementia Rating Scale—Sum of Boxes (CDR-SB), for which higher scores indicate worse outcomes. The trial was terminated for futility after 704 patients had completed the 104-week regimen.
Slomski A. Another Amyloid-beta Blocker Fails to Halt Dementia. JAMA. 2019;321(24):2396. doi:10.1001/jama.2019.7821
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: